Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6990559rdf:typepubmed:Citationlld:pubmed
pubmed-article:6990559lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:6990559lifeskim:mentionsumls-concept:C0150369lld:lifeskim
pubmed-article:6990559lifeskim:mentionsumls-concept:C0022671lld:lifeskim
pubmed-article:6990559lifeskim:mentionsumls-concept:C0007589lld:lifeskim
pubmed-article:6990559lifeskim:mentionsumls-concept:C0596402lld:lifeskim
pubmed-article:6990559lifeskim:mentionsumls-concept:C0035015lld:lifeskim
pubmed-article:6990559lifeskim:mentionsumls-concept:C1882923lld:lifeskim
pubmed-article:6990559lifeskim:mentionsumls-concept:C1548437lld:lifeskim
pubmed-article:6990559lifeskim:mentionsumls-concept:C1511938lld:lifeskim
pubmed-article:6990559pubmed:issue5lld:pubmed
pubmed-article:6990559pubmed:dateCreated1980-7-28lld:pubmed
pubmed-article:6990559pubmed:abstractTextPhytohemagglutinin (PHA)-induced cytotoxicity against adherent HeLa cells, a reproducible test for primary T cell cytotoxicity, was used in the followup of 34 renal transplant recipients and related to the outcome. During the 1st week, two uncomplicated cases showed a decrease in cytotoxicity of more than 20% and it remained low. One patient with a cytomegalovirus (CMV) infection showed a marked increase in cytotoxicity (37%) and it remained high. In 31 patients with a rejection episode, a change of -20 to +20% was observed. During the 2nd week, all 10 patients who developed an irreversible rejection showed an increase of more than 20% (mean, 29 +/- 8%), in contrast to only 2 of 21 patients with a reversible rejection (mean, -1 +/- 15%, P less than 0.001). There were no differences between these two groups in lymphocyte and T lymphocyte counts, or in prednisone or azathioprine dose or blood urea nitrogen levels. These results indicate that regular assessment of PHA-induced cytotoxicity may be useful in the followup of renal transplant patients.lld:pubmed
pubmed-article:6990559pubmed:languageenglld:pubmed
pubmed-article:6990559pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6990559pubmed:citationSubsetIMlld:pubmed
pubmed-article:6990559pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6990559pubmed:statusMEDLINElld:pubmed
pubmed-article:6990559pubmed:monthMaylld:pubmed
pubmed-article:6990559pubmed:issn0041-1337lld:pubmed
pubmed-article:6990559pubmed:authorpubmed-author:de GastG CGClld:pubmed
pubmed-article:6990559pubmed:authorpubmed-author:TegzessA MAMlld:pubmed
pubmed-article:6990559pubmed:authorpubmed-author:Huges-LawGGlld:pubmed
pubmed-article:6990559pubmed:issnTypePrintlld:pubmed
pubmed-article:6990559pubmed:volume29lld:pubmed
pubmed-article:6990559pubmed:ownerNLMlld:pubmed
pubmed-article:6990559pubmed:authorsCompleteYlld:pubmed
pubmed-article:6990559pubmed:pagination357-60lld:pubmed
pubmed-article:6990559pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:meshHeadingpubmed-meshheading:6990559-...lld:pubmed
pubmed-article:6990559pubmed:year1980lld:pubmed
pubmed-article:6990559pubmed:articleTitleDifferentiation between irreversible and reversible rejection in renal transplant patients by monitoring of phytohemagglutinin-induced cytotoxicity.lld:pubmed
pubmed-article:6990559pubmed:publicationTypeJournal Articlelld:pubmed